Simulations Plus (NASDAQ:SLP) Now Covered by Stephens

Stephens began coverage on shares of Simulations Plus (NASDAQ:SLP) in a research report sent to investors on Friday, MarketBeat.com reports. The brokerage issued an overweight rating and a $39.00 target price on the technology company’s stock.

A number of other brokerages have also recently weighed in on SLP. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, November 6th. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. BTIG Research dropped their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Simulations Plus Stock Performance

NASDAQ SLP traded down $0.94 during trading on Friday, reaching $28.77. 231,167 shares of the company’s stock were exchanged, compared to its average volume of 134,624. Simulations Plus has a 1 year low of $27.22 and a 1 year high of $51.22. The stock has a market cap of $577.41 million, a P/E ratio of 58.72 and a beta of 0.71. The company has a 50 day moving average price of $31.19 and a two-hundred day moving average price of $38.93.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same period in the prior year, the company posted $0.18 earnings per share. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. Research analysts forecast that Simulations Plus will post 1.12 EPS for the current fiscal year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00. Following the completion of the transaction, the director now owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 60,750 shares of company stock valued at $1,905,655. Company insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds have recently added to or reduced their stakes in SLP. First Horizon Advisors Inc. raised its stake in Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares during the last quarter. nVerses Capital LLC raised its position in shares of Simulations Plus by 1,100.0% in the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Simulations Plus during the first quarter worth approximately $57,000. Allspring Global Investments Holdings LLC acquired a new position in Simulations Plus in the 1st quarter valued at $70,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Simulations Plus during the third quarter worth $59,000. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.